Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 02 2022 - 4:30PM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, today announced that the American Society of Gene &
Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for
presentation at the 25th ASGCT Annual Meeting being held May 16-19,
2022, in-person in Washington, D.C. and in a virtual format.
Presentations will focus on the progression of Sangamo’s
pre-clinical programs emerging from its genomic engineering
platform.
“The data to be presented at ASGCT reflect the diversity and
versatility of Sangamo’s genomic engineering platform, which is
being deployed across a range of pre-clinical programs,” said Jason
Fontenot, Ph.D., Chief Scientific Officer at Sangamo. “We look
forward to demonstrating the robust pre-clinical knowledge and
innovation that continues to emerge from our research efforts, to
deliver transformative medicines to patients in need.”
Data to be presented at the ASGCT Annual Meeting include an oral
presentation of a study looking at Sangamo’s innovative genetically
engineered adeno-associated virus (AAV) capsid platform for
delivery to the central nervous system (CNS) after cerebrospinal
fluid administration. With protection from the blood-brain barrier,
current gene delivery to the CNS continues to be an obstacle.
Sangamo’s AAV capsids are designed to overcome that barrier,
providing broad CNS access while minimizing exposure to a patient’s
pre-existing anti-AAV antibodies. Another Sangamo AAV capsid
presentation will outline CNS delivery via intravenous
administration.
Other presentations at the ASGCT Annual Meeting will showcase
how Sangamo is advancing its proprietary zinc finger platform
development efforts, including its high-efficiency base-editing
program in human cells and its use of zinc finger transcription
factors for multiplex engineering of CAR-T cells without imparting
changes to the genetic code. Sangamo will also present data from
its CAR-Treg cell therapy platform, including outlining
advancements in pre-clinical allogeneic Treg engineering.
ASGCT Annual Meeting Presentations and
Invited Sessions
Viral Engineering for the Central
Nervous System
- Engineered AAV Capsids with Exhibit Improved Transduction of
the Central Nervous System after CSF Administration
- Abstract No. 441
- Oral Presentation – May 17; 4:00-4:15 pm ET
- Evaluation of a Human Neurovascular Model to Complement a
Parallel Non-Human Primate Selection for Blood Brain Barrier
Penetrant AAV Capsids
- Abstract No. 899
- Poster Presentation – May 18; 5:30-6:30 pm ET (Board No.
W-25)
Genomic Engineering Platform
Evolution
- A Compact Zinc Finger Architecture for High-Efficiency Base
Editing in Human Cells
- Abstract No. 560
- Poster Presentation – May 17; 5:30-6:30 ET (Board No.
TU-65)
- Durable, Multiplexed, Cell Engineering Using Zinc-Finger Guided
Transcriptional Regulators Delivered via a Single Viral Particle
- Abstract No. 339
- Poster Presentation – May 16; 5:30-6:30 pm ET (Board No.
M-220)
- Genome Orthogonal Zinc Finger Proteins for the Development of
Genomic Medicines
- Abstract No. 946
- Poster Presentation – May 18; 5:30-6:30 pm ET (Board No.
W-72)
- Zinc Finger Nuclease/AAV6-Mediatred Factor IX (FIX) Insertion
into B cells Results in Sustained Therapeutic FIX-levels in vivo
After Using a GMP-like Differentiation Culture System
- Abstract No. 702
- Poster Presentation – May 17; 5:30-6:30pm ET (Board No.
TU-207)
Engineered CAR-Treg
Platform
- STEADFAST: A First-in-Human Study Assessing HLA-A*02-Chimeric
Antigen Receptor Regulatory T Cells in Renal Transplantation
- Abstract No. 798
- Poster Presentation – May 17; 5:30-6:30 pm ET (Board No.
Tu-303)
- Engineering of Allogeneic T Regulatory Cells Expressing a
Chimeric Antigen Receptor (Allo-CAR-Tregs) Using Zinc Finger
Nuclease/AAV6-Mediated Editing
- Abstract No. 1112
- Poster Presentation – May 18; 5:30-6:30 pm ET (Board No.
W-238)
All abstracts for the ASGCT Annual Meeting are available on
ASGCT’s website.
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biopharmaceutical
company with a robust genomic medicines pipeline. Using
ground-breaking science, including our proprietary zinc finger
genome engineering technology, and manufacturing expertise, Sangamo
aims to create new genomic medicines for patients suffering from
diseases for which existing treatment options are inadequate or
currently don’t exist. For more information about Sangamo, visit
www.sangamo.com.
Sangamo Forward Looking Statements
This press release contains forward-looking statements based on
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements relating to Sangamo’s
technologies, the presentation of data from various therapeutic and
research programs and the potential of these programs to
demonstrate therapeutic benefit and transform the lives of
patients. These statements are not guarantees of future performance
and are subject to certain risks and uncertainties that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, the research development
process, including the results of clinical trials; the regulatory
approval process for product candidates; and the potential for
technological developments that obviate technologies used by
Sangamo. Actual results may differ from those projected in
forward-looking statements due to risks and uncertainties that
exist in Sangamo's operations and business. These risks and
uncertainties are described more fully in our Securities and
Exchange Commission filings and reports, including in our Annual
Report on Form 10-K for the year ended December 31, 2021.
Forward-looking statements contained in this announcement are made
as of this date, and Sangamo undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005671/en/
Investor Relations & Media
Inquiries Louise
Wilkie ir@sangamo.com media@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Apr 2023 to Apr 2024